Invirsa

Columbus, United States

Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.

$7.7M raised

Jun 2023

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Invirsa raised?

Invirsa has raised $7.7M in total funding. The most recent round was Series B. The last funding was announced in June 2023.

Who are Invirsa's investors?

Invirsa's investors include Jumpstart Ventures, Rev1 Ventures, CincyTech, JobsOhio.

Where is Invirsa headquartered?

Invirsa is headquartered in Columbus, United States.

What does Invirsa do?

Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.

What stage is Invirsa at?

Invirsa is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 14, 2023.

MLA

"Invirsa — Funding & Investors." VCBacked, June 14, 2023, https://www.vcbacked.co/company/invirsa. Accessed July 2, 2026.

APA

VCBacked. (2023). Invirsa — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/invirsa

Wikipedia (cite web)

{{cite web |title=Invirsa — Funding & Investors |url=https://www.vcbacked.co/company/invirsa |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 14, 2023.